secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dianthus Therapeutics, Inc. /DE/ (DNTH)
CIK:        0001690585
Form:       8-K
Filed at:   2025-05-22T23:59:59+00:00
Accession:  0000950170-25-076304
Event type: leadership
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.02, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Dianthus director Moulder resigns; Read appointed as Class III director
-----------------------------------------------------------------------

- Leon O. Moulder, Jr. resigned from Board effective May 22, 2025, with no disagreement.
- Board appointed Simon Read, Ph.D. as Class III director and to S&T and N&CG Committees.
- Dr. Read receives initial option for 25,000 shares vesting over 3 years; cash compensation of $40k/yr plus $5k per committee.
- Annual meeting elected Garcia and Soteropoulos as Class I directors; advisory vote approved exec compensation; Deloitte ratified as auditor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1690585/000095017025076304/0000950170-25-076304-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1690585/000095017025076304/dnth-20250522.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-076304

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer